

Assessed for Eligibility (n=27)

Excluded (n=9)
- Screen Failure (n=8)
- Lost to Follow-Up (n=1)

Initiated & Completed Open Label Treatment with Omalizumab (n=18)
- Males (n=6)
- Females (n=12)